KAINOS Laboratories (TSE:4556) PE Ratio: 21.57 (As of Jul. 11, 2026) — 148% Above Median


TSE:4556 KAINOS Laboratories Inc TSE:4556
39 GF Score
Price 円2,268.00
GF Value 円1,281.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is KAINOS Laboratories PE Ratio?

KAINOS Laboratories TSE:4556 39 PE Ratio is 21.57 as of Jul. 11, 2026, which is 148% above its 10-year median of 8.69. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,281.99 (Significantly Overvalued). The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-11), KAINOS Laboratories's share price is 円2268.00. KAINOS Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円105.16. Therefore, KAINOS Laboratories's PE Ratio for today is 21.57.

Warning Sign:

KAINOS Laboratories Inc stock PE Ratio (=21.36) is close to 10-year high of 21.42.

During the past 13 years, KAINOS Laboratories's highest PE Ratio was 21.57. The lowest was 7.26. And the median was 8.69.

KAINOS Laboratories's EPS (Diluted) for the six months ended in Mar. 2026 was 円32.51. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円105.16.

As of today (2026-07-11), KAINOS Laboratories's share price is 円2268.00. KAINOS Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円129.43. Therefore, KAINOS Laboratories's PE Ratio without NRI ratio for today is 17.52.

During the past 13 years, KAINOS Laboratories's highest PE Ratio without NRI was 17.52. The lowest was 6.68. And the median was 8.46.

KAINOS Laboratories's EPS without NRI for the six months ended in Mar. 2026 was 円56.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円129.43.

During the past 12 months, KAINOS Laboratories's average EPS without NRI Growth Rate was -13.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was -1.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 4.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.70% per year.

During the past 13 years, KAINOS Laboratories's highest 3-Year average EPS without NRI Growth Rate was 722.20% per year. The lowest was -1.40% per year. And the median was 10.60% per year.

KAINOS Laboratories's EPS (Basic) for the six months ended in Mar. 2026 was 円33.54. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円106.19.

Back to Basics: PE Ratio


KAINOS Laboratories  (TSE:4556) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


KAINOS Laboratories PE Ratio Related Terms


KAINOS Laboratories PE Ratio Historical Data

* Premium members only.

The historical data trend for KAINOS Laboratories's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories PE Ratio Chart

KAINOS Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.95 7.65 7.94 8.24 21.31

KAINOS Laboratories Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 18.17 8.24 At Loss 21.31

TSE:4556 vs ISRG, BDX, MDLN: PE Ratio Comparison

For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KAINOS Laboratories PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's PE Ratio distribution charts can be found below:

* The bar in red indicates where KAINOS Laboratories's PE Ratio falls into.


TSE:4556
39GF Score
KAINOS Laboratories Inc TSE:4556
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KAINOS Laboratories PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

KAINOS Laboratories's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=2268.00/105.161
=21.57

KAINOS Laboratories's Share Price of today is 円2268.00.
For company reported semi-annually, KAINOS Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円105.16.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 21.57 mean?
KAINOS Laboratories (TSE:4556) has a PE Ratio of 21.57 as of Jul. 11, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on KAINOS Laboratories and its competitors. This is 148% above median its historical median of 8.69. Over the past decade, KAINOS Laboratories' PE Ratio has ranged from 7.26 to 21.57.
Is KAINOS Laboratories' PE Ratio too high?
KAINOS Laboratories' current PE Ratio of 21.57 is 148% above median its 10-year median of 8.69. Over the past 10 years, this metric has ranged from a low of 7.26 to a high of 21.57. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' PE Ratio compare to ISRG and BDX?
KAINOS Laboratories' PE Ratio of 21.57 can be compared against companies in the Medical Devices & Instruments industry. Historically, KAINOS Laboratories' own PE Ratio has ranged from 7.26 to 21.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on KAINOS Laboratories and its competitors. KAINOS Laboratories's current PE Ratio is 21.57, which is 148% above median its own 10-year median of 8.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,281.99, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current PE Ratio is 21.57, which is 148% above median its 10-year median of 8.69. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current PE Ratio is 21.57 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?

Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued. The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,281.99. GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.

Key valuation signals for TSE:4556:

  • PE Ratio: 21.57 (148% above median its 10-year median of 8.69)
  • GF Value™: 円1,281.99 vs. price of 円2,268.00 (76.9% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


KAINOS Laboratories Business Description

Address 38-18, Hongo 2-chome, Bunkyo-ku, Tokyo, JPN
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score

Get the complete analysis for TSE:4556

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,268.00
Price
円1,281.99
GF Value